Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing
Completed · Phase 1 · NCT05547542
Conditions: Opioid Use Disorder
At a glance
- Research payments reported, 2025
- $177,517
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 19
About the trial
- Sponsor
- Cerevel Therapeutics, LLC (with National Institute on Drug Abuse (NIDA))
- Tested
- CVL-354 (drug), [11C]-LY2795050 (drug), [11C]-carfentanil (drug)
- Dates
- Started 2023-03-02; completion 2024-08-06
- Results posted
- Not yet
The primary purpose of this study is to assess the target occupancy at kappa and mu opioid receptors in the brain after single oral doses of CVL-354 in healthy adult participants.
From ClinicalTrials.gov, last updated 2025-07-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $177,517 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $177,517
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.